

Author Index

- A**
Aching-Kawecka, J, 41
Aguirre, AJ, 237
Alcantara Llaguno, SR, 31
Alderton, G, 299, 317, 323, 341
Allen, E, 21
Annunziato, S, 141
- B**
Barazas, M, 141
Berger, T, 85
Bergers, G, 21, 299
Bissell, MJ, 207
Boehm, JS, 237
Brugge, JS, 281, 301
Bruna, A, 227
- C**
Caldas, C, 227
Cho, H, 113
Cichowski, K, 304
Clark, SJ, 41, 306
- D**
Dang, CV, 73
- E**
Evan, G, 309
- F**
Faham, N, 177
Fearon, DT, 219
Feigin, ME, 231
Furita, S, 207
- G**
George, BM, 1
Gill, JG, 163
- H**
Graubert, A, 105
Griffith, M, 105
Griffith, OL, 105
Guo, JY, 73
- H**
Haber, DA, 269, 311
Hahn, WC, 237
Hoffman, A, 105
Hong, AL, 237
Howard, TP, 237
Huang, CH, 257
Hundal, J, 105
- J**
Jonkers, J, 141
- K**
Kadoch, C, 53
Kaelin, WG, 113, 314
Kalluri, R, 275, 317
Kang, Y, 151
Kao, KS, 1
Kiberstis, P, 304, 326, 344
Kiwala, S, 105
Kvajo, M, 306, 320, 331
- L**
LeBleu, VS, 275
Letai, A, 131
Li, W, 151
Lockwood, WW, 247
Lowe, SW, 257, 320
Lozano, G, 37, 323
Lyden, D, 326
- M**
Maheswaran, S, 269
Mak, TW, 85
- Manchado, E, 257**
Mardis, ER, 105, 328
Marjon, KD, 1
McCracken, MN, 1
McKenna, E, 311, 338, 354, 360
McMichael, J, 105
Miller, CA, 105
Missiaen, R, 21
Miyamoto, DT, 269
Morrison, SJ, 163, 331
Muranen, T, 281
- N**
Neel, B, 334
- O**
Oudin, MJ, 189
- P**
Palm, W, 67
Parada, LF, 31, 336
Pattabiraman, DR, 11
Piskounova, E, 163
Polyak, K, 123
Potter, DS, 131
Pulice, JL, 53
- R**
Raveh, T, 1
Rinne, M, 237
Roe, JS, 61
Rottenberg, S, 141
Rueda, OM, 227
- S**
Saunders, ME, 85
Sawyer, C, 291
Sever, R, 301, 309, 328, 334
- Shaw, RJ, 93**
Shiu, S, 123
Stratton, M, 338
Svensson, RU, 93
- T**
Taberlay, PC, 41
Tasdemir, N, 257
Thompson, CB, 67
Ting, DT, 269
Toner, M, 269
Tschaharganeh, DF, 257
Tsherniak, A, 237
Tuveson, DA, 231, 341
- U**
Unni, AM, 247
- V**
Vakoc, CR, 61, 344
Varmus, H, 247, 347
Vazquez, F, 237
Vousden, K, 351
- W**
Walker, J, 105
Weaver, VM, 189, 354
Weinberg, RA, 11, 357
Weissman, IL, 1
Welm, AL, 177
White, E, 73, 360
Wilkinson, JE, 257
Witkowski, J, 314, 336, 347, 351, 357
- X**
Xie, X, 31
Zheng, H, 151

This is a free sample of content from Cold Spring Harbor Symposia on Quantitative Biology. Volume LXXX1: Targeting Cancer.
[Click here](#) for more information on how to buy the book.

Subject Index

A

- ABT-737, 136
- ACC. *See* Acetyl-CoA carboxylase
- Acetyl-CoA carboxylase (ACC)
 - fatty acid metabolism regulation, 93, 96–97
 - inhibitor development, 98–99
 - non-small cell lung cancer, fatty acid synthesis as metabolic liability, 99–100
 - therapeutic targeting, 96, 98–100
- Acetyl-CoA synthetase short-chain family member 2 (ACSS2), therapeutic targeting, 94–95
- ACLY. *See* ATP citrate lyase
- ACSS2. *See* Acetyl-CoA synthetase short-chain family member 2
- Acute lymphoblastic leukemia (ALL), BH3 profiling and apoptosis priming, 137
- Acute myeloid leukemia (AML)
 - BRD4
 - effectors, 63–64
 - function and therapeutic targeting, 61–63
 - IDH1 mutations, 88
- ADAMTS1, bone metastasis promotion, 153–155
- AKT, 90, 93, 95, 197, 233
- ALL. *See* Acute lymphoblastic leukemia
- AML. *See* Acute myeloid leukemia
- Anergy, therapeutic targeting, 86
- Aneuploidy, therapeutic targeting, 90
- Angiogenesis
 - cell growth in vascularly compromised tumors, 69–70
 - innate immunity and antiangiogenic therapy, 22–24
 - metabolic endothelial cell adaptation, 23, 25
 - metabolic tumor cell adaptations to antiangiogenic therapy, 25–27
 - overview in cancer, 21–22
- Antioxidants. *See* Reactive oxygen species
- APC, 320
- APOBEC, 338–339
- Apoptosis
 - BH3 proteins
 - BCL-2 targeting, 135–137
 - profiling, 134–135, 137
 - promotion, 132–133
 - intrinsic pathway, 131–133
 - priming, 133–134, 137–138
- ARID1A, 54–57, 242–243
- Atg7, 75–77
- ATM, 88–89
- ATP citrate lyase (ACLY), therapeutic targeting, 93, 95

Autophagy

- basal autophagy in tumors, 73
- cancer metabolism promotion, 76–77, 383
- macromolecule recycling, 75–76
- prospects for study, 77
- survival in starvation, 73–75
- tumor dependence, 75, 360
- tumorigenesis promotion, 75

B

- BAF, 53–58
- BCL-2
 - anti-apoptotic activity, 132
 - BH3 protein targeting, 135–137
- BCR-ABL, 242, 247, 292, 329
- Bergers, G, interview, 299–300
- BH3 proteins. *See* Mimetics
- Bmal1, 79–80, 82
- BMS-777607, 182
- Bone metastasis
 - epidemiology, 151
 - genes, 152–153
 - osteoclast microRNA studies, 157
 - progression mechanisms, 151–152
 - tumor–stroma interactions
 - ADAMTS1 and MMP-1 promotion of metastasis, 153–155
 - therapeutic targeting
 - Jagged1, 155–157
 - transforming growth factor- β , 155–157
- BRAF, 251, 285, 293–294, 360
- BRCA1, oxidative stress in cancer, 89–90
- BRD proteins
 - BRD4
 - acute myeloid leukemia
 - effectors, 63–64
 - function and therapeutic targeting, 61–63
 - hematopoietic lineage transcription factor cofactor, 63
 - therapeutic targeting, 285, 344–346
 - breast cancer
 - inhibitors in triple-negative breast cancer, 125–126
 - proliferation role in estrogen receptor-positive cancers, 124–125
 - functional overview, 123–124
 - inhibitor resistance mechanisms, 126–128
- Breast cancer. *See also* Mammary tumor organoid
- BRD proteins
 - inhibitors in triple-negative breast cancer, 125–126
 - proliferation role in estrogen receptor-positive cancers, 124–125

- circulating tumor cell analysis of intratumoral heterogeneity, 271–272
- classification, 227
- epidemiology, 141
- lineage switching and therapy resistance, 287–288
- mouse models
 - basal-like cancer
 - BRCA mutations, 143
 - PARP inhibitor resistance mechanisms, 144–146
 - preclinical trials, 143–144
 - invasive lobular carcinoma, 142–144
 - mammary tumor organoids, 147–148
 - nongerm-line models, 146–147
 - prospects, 148
 - xenograft collection and heterogeneity analysis, 227–230
- BRG1, 53, 55, 58
- Brugge, J, interview, 301–302

C

- Cancer immunogenomics
 - neoantigen prediction, 105–107
 - vaccine creation case reports, 107–110
- Cancer stem cell (CSC)
 - epithelial-to-mesenchymal transition and stemness, 12–13
 - glioblastoma multiforme
 - in vivo model, 33
 - nestin–green fluorescent protein transgene characterization, 34
 - overview, 33
 - prospects for study, 34
 - therapeutic resistance, 34
 - leukemia, 1–2, 5–7
- CD47
 - innate immune invasion, 6–7
 - leukemic stem cell expression, 1–2
- CDH1, 13–14, 16
- CFI400945, 90
- Cichowski, K, interview, 304–305
- Circulating tumor cells (CTCs)
 - overview, 311–313
 - single-cell analysis
 - intratumoral heterogeneity studies
 - breast cancer, 271–272
 - pancreatic cancer, 271
 - prostate cancer, 270–271
 - microfluidic isolation, 269–270
 - overview, 269
 - prospects for study, 273
 - tumor evolution monitoring, 272–273
- Clark, S, interview, 306–308
- Clock, 79–80, 82
- Coffin–Siris syndrome (CSS), 56–57

- CpG islands, 306–307
CRISPR–Cas9
 breast cancer mouse models, 146–147
 large-scale cancer dependency
 functional genomics
 screens, 241–242
CRKL, 238
CSC. *See* Cancer stem cell
CSS. *See* Coffin–Siris syndrome
CTCF, 41, 43–44, 49
CTCs. *See* Circulating tumor cells
CTLA4, 295
Cummings Lecture, 291–295
CYCLOPS, 243, 285–286
D2HG. *See* 2-Hydroxyglutarate
- E**
- EGFR*, lung cancer mutations, 249–251, 253
EMT. *See* Epithelial-to-mesenchymal transition
Epithelial-to-mesenchymal transition (EMT)
 classification, 11
 epithelial trait loss during malignancy, 13–15
 genes, 358–359
 mesenchymal trait acquisition, 15
 metastasis studies, 12
 program redefining, 5
 stemness role, 12–13
 therapeutic targeting, 16–17
 tumor progression, 11–12
ERK, 302–304
Evan, G, interview, 309–310
Exosome
 biogenesis, 275
 double-stranded DNA
 functions, 277–278
 identification, 277
 mutation detection, 277
 prospects for study, 278–279
 drug delivery, 318
 overview, 275–277
Extracellular matrix. *See* Mammary tumor organoid; Tumor microenvironment
- F**
- FAK, 195–196, 198
FAM83 oncogenes, 211–212
FAS. *See* Fatty acid synthase
Fatty acid synthase (FAS)
 elevation in tumors, 95
 fatty acid synthesis overview, 93–95
 metabolic tumor cell adaptations to
 antiangiogenic therapy, 26
Fibronectin, 195
FRS2, 238
Functional genomics, cancer
 challenges, 243
 large-scale cancer dependency screens
 cancer dependency types, 242–243
 CRISPR–Cas9, 241–242
 RNA interference, 239–240
 small molecule screens, 242
 overview, 237–238
 screens for alterations in cancer
- allele variants, 238–239
copy number alterations, 238
- G**
- GATA3, 55
GBM. *See* Glioblastoma multiforme
Gleevec, 292
Glioblastoma multiforme (GBM)
 cancer stem cells
 in vivo model, 33
 nestin–green fluorescent protein
 transgene characterization, 34
 overview, 33
 prospects for study, 34
 therapeutic resistance, 34
 cancer vaccines, 107–110
 cell memory, 32
 lineages, 31
 metabolic tumor cell adaptations to
 antiangiogenic therapy, 25
 progenitor cells, 32–33
 types in mouse models, 31–32
Glutamine, cancer cell uptake, 67–68
GSK3 β , 6
- H**
- Haber, D, interview, 311–313
Hematopoietic stem cell (HSC)
 characterization, 2–3
 Hoxb5 expression in long-term stem
 cells, 4–5
 leukemia mutations, 5
 leukemic stem cell comparison,
 5–7
 TLS cells, 2–3
 transplantation, 1
HER2, 13
HGF, 159
HIF. *See* Hypoxia-inducible factor
Hoxb5, hematopoietic stem cell
 expression, 4–5
HSC. *See* Hematopoietic stem cell
HUGL2, 13
2-Hydroxyglutarate (D2HG), oncogenicity,
 89, 314
Hypoxia-inducible factor (HIF)
 functional overview, 114
 HIF2 in clear cell renal cell carcinoma
 carcinogenesis role, 115–116
 therapeutic targeting, 116–118
 regulation by VHL and oxygen, 115,
 314
 structure, 114
- I**
- IDH. *See* Isocitrate dehydrogenase
Innate immunity
 antiangiogenic therapy, 22–24
 therapeutic targeting, 86
Isocitrate dehydrogenase (IDH), mutation
 effects on ATM and NOTCH,
 88–89
 2-hydroxyglutarate oncogenicity, 89
 mouse models, 88
 tumors, 87–88, 321
- J**
- Jagged1, therapeutic targeting in bone
 metastasis, 155–157
JQ1, 124–128, 344–346
- K**
- Kaelin, W, interview, 314–318
Kalluri, R, interview, 317–319
KEAP1, 164
c-Kit, hematopoietic stem cell
 expression, 3
KRAS
 lung cancer mutations, 249–251, 253
 pancreatic cancer mutations, 232, 247
 survival of tumors, 360–361
- L**
- LAMA3, 213–214
Leukemia
 hematopoietic stem cell mutations, 5
 leukemic stem cells, 1–2, 5–6
lgf2, 13
LKB1, 195
Long-range epigenetic silencing (LRES),
 prostate cancer, 47–49
Lowe, S, interview, 320–322
LOXL2, 199
Lozano, G, interview, 323–325
LRES. *See* Long-range epigenetic
 silencing
Lung cancer
 KRAS mutations, 249–251, 263
 lineage switching and therapy resis-
 tance, 287
 non-small cell lung cancer, fatty acid
 synthesis as metabolic
 liability, 99–100
Lyden, D, interview, 326–327
- M**
- Macropinocytosis, regulation, 70
MAGE-A1, 105
Mammary tumor organoid
 human cells
 extracellular matrix–nucleus
 linkage, 213–215
 formation on three-dimensional
 substrata, 208–210
 morphogenesis assay and
 applications, 210–213
 overview, 207
 mouse models, 147–148
Mardis, E, interview, 328–330
Matrix metalloproteinases (MMPs)
 MMP-1 and promotion of bone
 metastasis, 153–155
 MMP-9, 210
MCT cotransporters, 192
Mdm2, 37–38
MED1, 126
MET, 170, 182, 327
Microenvironment. *See* Tumor
 microenvironment

- MicroRNA, osteoclast microRNA in bone metastasis, 157
- Mitochondrial outer membrane permeabilization (MOMP), 131–132, 135
- MMPs. *See* Matrix metalloproteinases
- MOMP. *See* Mitochondrial outer membrane permeabilization
- Morrison, S, interview, 331–333
- MSP, 179–180
- MTAP*, 243
- mTORC1
cell growth effector, 71
lysosomal protein degradation regulation, 70
- MYC, 310
circadian clock perturbation, 79–80
timing of metabolic therapies, 80–82
- N**
- NADPH, regeneration, 168–170
- Navitoclax, 136–137
- ND-646, 99–100
- Neel, B, interview, 334–335
- NHE1, 192
- NOTCH, 88–89
- NRF2, 164–165, 167–168, 232–233, 284
- Nrp1, 22, 47
- Nutrient uptake, cancer cells
glucose, 67–68
glutamine, 67–68
macropinocytosis regulation, 70
nutrient depletion survival, 68–69, 71
signal transduction, 67–68
- O**
- Olaparib, 144–145
- Oncogene mutations
agonistic synthetic lethality, 252
general features, 247–248
genotype complexities, 248
lung cancer mutually exclusive oncogenes, 248–252
patterns and mutual exclusivity, 248
prospects for study, 253–254
- Organoid. *See* Mammary tumor organoid
- OTX-015, 62
- Oxidative stress. *See* Reactive oxygen species
- P**
- p53, 142, 320–321, 323–325, 352
DNA damage response, 38
Mdm2 alleles and physiological outcomes, 37–38
tumor suppressor pathway, 38–39
turnover, 37
- Pancreatic cancer
challenges and opportunities for study, 233–234
circulating tumor cell analysis of intratumoral heterogeneity, 271
KRAS mutations, 232
mouse models, 231–232
- Nrf2 in progression, 232–233
organoid models, 231–232
tumor microenvironment, 233
- Parada, L, interview, 336–337
- PARP inhibitors, 143–144, 301
- PATJ*, 13
- PAX8*, 238
- PBAF, 53–54
- PD-L1, 300
- PDGF, 164, 190, 194
- PDGFR β , 258
- PFKFB3, 23, 25
- PGC-1 α , 170
- PHGDH, 168
- PIK3CA*, 238
- PLXNA2*, 49
- PRMT5*, 243
- Prostate cancer
circulating tumor cell analysis of intratumoral heterogeneity, 270–271
differential chromatin interactions, 44, 46–47
long-range epigenetic silencing, 47–49
topologically associated domain disruptions, 41–45
- PTEN, 90, 164
- PTP1B, 334–335
- R**
- Rac1, 196
- RAD21, 41
- RANKL, 151–152
- Ras, 310
- RCC. *See* Renal cell carcinoma
- Reactive oxygen species (ROS)
antioxidants
clinical trials in cancer prevention, 165–166
treatment, 165, 167
defenses, 164–165
cancer initiation and progression role, 167
handling in cancer cells, 87, 168–170
metastasis role, 167–168
serine limitation effects, 352
sources, 163–164
therapeutic targeting, 89–90
- Receptor d'origine nantais (RON)
cancer activation, 179–180
cell-autonomous versus non-cell-autonomous functions in cancer progression, 181–182
history of study, 177
signaling
downstream pathways in cancer progression, 180–181
ligand-dependent versus ligand-independent, 179
structure, 177–178
therapeutic targeting, 182–183
- Renal cell carcinoma (RCC)
clear cell carcinoma
genetics, 113–114
HIF2
carcinogenesis role, 115–116
therapeutic targeting, 116–118
metabolic tumor cell adaptations to antiangiogenic therapy, 26
- RNA interference
drug target screens
identification of targets, 258–260
therapeutic index establishment
inducible and reversible transgenic mice, 263, 265–266
liver regeneration studies, 262–264
overview, 262
validation
in vitro, 260–261
in vivo, 261–262
large-scale cancer dependency screens, 239–240
- RNF213, 335
- ROCK, 355
- RON. *See* Receptor d'origine nantais
- ROS. *See* Reactive oxygen species
- S**
- Sawyers, C, Dorcas Cummings Lecture, 291–295
- SDF-1, 195
- Single-cell analysis. *See* Circulating tumor cells
- SMAD4, 190
- SMARCB1, 53–55
- SOD. *See* Superoxide dismutase
- SREBPs. *See* Sterol regulatory element-binding proteins
- Sterol regulatory element-binding proteins (SREBPs), 93
- STK11*, 250
- Stratton, M, interview, 338–340
- Superoxide dismutase (SOD), 164
- SWI/SNF
gain-of-function, 56
intellectual disability syndrome point mutations, 56–57
overview of mammalian complexes, 53–54
promoter and enhancer state maintenance, 57–58
prospects for study, 58
sequencing studies in cancer, 54–55
tumor suppression, 55–56
- T**
- TAD. *See* Topologically associated domain
- Taverson, D, interview, 31–343
- T-cell
chimeric receptor T-cell therapy, 286–287
paucity in tumors
CXCR3
impairment in colorectal tumor model, 221–222
chemokine mediation of T-cell accumulation, 220–221
inhibition by CXCR4, 222–223
immune escape, 219–220
overview, 219
prospects for study, 223–224
therapeutic targeting, 85–86
- Tenascin C, 190–191
- TET2, leukemia mutations, 5

- TGF- β . *See* Transforming growth factor- β
TME. *See* Tumor microenvironment
Topologically associated domain (TAD),
 prostate cancer disruptions,
 41–45
Transforming growth factor- β (TGF- β),
 therapeutic targeting in
 bone metastasis, 155–157
TRAP, 154
TRIM33, 127
Tumor microenvironment (TME)
 bone metastasis
 ADAMTS1 and MMP-1
 promotion, 153–155
 niches beyond osteoclastogenesis,
 157–159
 gradients
 chemokines and growth factors,
 190
 directional migration
 alignotaxis, 196
 chemotaxis, 194–195
 durotaxis, 196
 galvanotaxis, 196–197
 haptotaxis, 195–196
 techniques for study, 193–194
 electrical field alterations, 192–193
 extracellular matrix changes, 190–
 191
 hypoxia establishment, 192
 overview, 189–190
 pH gradient inversion, 192, 197
 prospects for study, 199–201
 stiffness gradients, 191–192
 therapeutic targeting for metastasis
 prevention
 disruption of gradient, 198–199
 exploitation of gradient, 199
 prediction of metastasis, 197
 receptor and signaling block-
 ade, 197–198
 lineage switching and therapy resis-
 tance, 288
 pancreatic cancer, 233
 prospects for study, 284–285
 therapeutic targeting, 86
TWIST, 126
- V**
- Vaccines. *See* Cancer immunogenomics
Vakoc, C, interview, 344–346
Varmus, H, interview, 347–350
Vascular endothelial growth factor
 (VEGF), 21–22, 27, 116,
 159, 190, 288, 299–300,
 314–315
VCAM-1, 159
VEGF. *See* Vascular endothelial growth
 factor
Venetoclax, 137
VHL. *See* von Hippel–Lindau protein
von Hippel–Lindau protein (VHL),
 314
 clear cell renal cell carcinoma genetics,
 113–114
 hypoxia-inducible factor regulation,
 115
 tumor suppression, 114
Vousden, K, interview, 351–353
- W**
- Warburg effect, 87
Weaver, V, interview, 354–356
Weinberg, R, interview, 357–359
White, E, interview, 360–361
- Y**
- YAP1*, 238